Heart failure & cardiomyopathies
Baseline characteristics of patients in the randomized study to investigate the efficacy and safety of ferric carboxymaltose as treatment for heart failure with iron deficiency: HEART-FID trial
Authors' conclusion
Patients enrolled in HEART-FID were similar to those enrolled in other contemporary HFrEF trials and registries, including trials of intravenous iron in HFrEF. However, the HEART-FID cohort is substantially larger and more racially diverse than prior trials of intravenous iron in HFrEF.
Study context
- Population
- Patients with HF with reduced ejection fraction (HFrEF) and iron deficiency randomised in HEART-FID (ferric carboxymaltose)randomised
- Participants
- 3,065 patients
- Comparison
- HEART-FID participants vs patients in other contemporary HFrEF trials, including IV iron trials
Primary result
As reported in the abstract
Baseline characteristics · median baseline
- Age, median (IQR), years
- 69.7 (62.0-76.5)
- Female
- 1,037 (33.8%)
- Black
- 322 (10.5%)
- EF, median (IQR)
- 32% (25%-37%)
- Ischaemic etiology
- 1,837 (60.0%)
- NT-proBNP, median (IQR), pg/mL
- 1,462 (721-2,966)
- Haemoglobin, median (IQR), g/dL
- 12.6 (11.6-13.6)
- 6-minute walk distance, median (IQR), m
- 272 (196-350)
- AF/flutter
- 43.7%
- T2DM
- 45.2%
- Beta-blocker
- 92.5%
- ACEi/ARB/ARNI
- 86.1%
- ARNI
- 29.7%
- Mineralocorticoid antagonist (MRA)
- 55.6%
Further findings
Comparison with recent HFrEF trials
- Similar baseline demographics and clinical characteristics; greater proportion of women and Black participants in HEART-FID
Original publication
Baseline characteristics of patients in the randomized study to investigate the efficacy and safety of ferric carboxymaltose as treatment for heart failure with iron deficiency: HEART-FID trial. Am Heart J. Published 19 August 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →